Phase 2 Uveitis Trial (NCT03580343)

Phase 2 Uveitis Trial NCT03580343 Sponsor: Washington University School of Medicine Condition: Uveitis

Printed from Voxsanity (voxsanity.com.au) — NCT03580343 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Uveitis

Trial results

AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

According to the results reported on ClinicalTrials.gov, this trial enrolled 5 participants, all of whom were in a single group receiving a treatment called tofacitinib. Four of the five participants completed the study, while one did not finish. The trial was measuring a combined ("composite") outcome called "treatment failure," which was defined as any one of the following occurring: new areas of eye inflammation appearing compared to the start of the trial, a significant worsening of inflammation inside the eye (measured by the amount of cells visible in specific parts of the eye), or a meaningful drop in vision as measured on a standard eye chart. The reported data shows that, out of the 5 participants, 0 met the criteria for "treatment failure" during the study period. In other words, according to the reported numbers, none of the participants experienced the specific worsening events that the trial was tracking. It is worth noting that this was a very small number of participants, and no other outcome measures (such as secondary outcomes) appear to have been reported in the data submitted to ClinicalTrials.gov. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.

View full results on ClinicalTrials.gov ↗

These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

You have been diagnosed with uveitis (inflammation inside the eye)
Your uveitis has responded to steroid treatment in the past
Your condition is currently active and requires you to take at least 10mg of prednisone (or an equivalent steroid medication) every day

Who may not be able to join:

You have a suspected or confirmed infection in your eye
You have a long-term or recurring infection, such as HIV
You have kidney problems that would make it unsafe to take the study drug, tofacitinib (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 28 July 2026

Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.

Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I found the following past clinical trial relevant to my condition, and wanted to raise it with you. It is no longer recruiting, but I wanted to ask whether similar active trials exist, or whether its results are relevant to my care:

Trial: NCT03580343

Sponsor: Washington University School of Medicine

Phase: Phase 2

Status: Status unknown

Condition: Uveitis

More information: https://clinicaltrials.gov/study/NCT03580343

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

You have been diagnosed with uveitis (inflammation inside the eye)
Your uveitis has responded to steroid treatment in the past
Your condition is currently active and requires you to take at least 10mg of prednisone (or an equivalent steroid medication) every day

Who may not be able to join:

You have a suspected or confirmed infection in your eye
You have a long-term or recurring infection, such as HIV
You have kidney problems that would make it unsafe to take the study drug, tofacitinib (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 28 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Status unknown

Phase

Phase 2

Sponsor

Washington University School of Medicine

Registry

ClinicalTrials.gov

Start date

4 April 2019

Est. completion

1 December 2019

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Treatment Failure (Composite Outcome)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov